Bain Capital led a $150m Series B round in Alkeus Pharmaceuticals.

Bain Capital led a $150m Series B round in Alkeus Pharmaceuticals, a biopharmaceutical company, with participation from TCGX, Wellington Management and Sofinnova Investments. “The proceeds from this $150m financing will allow Alkeus to expand our team and drive gildeuretinol towards NDA submission and FDA approval as rapidly as possible,” Leonide Saad, Alkeus CEO, President, and Co-Founder.